Annexon Q2 net loss widens to $55.3 million; adds Month 24 endpoint to GA trial
Annexon reported a wider second-quarter 2026 net loss of $55.3 million, or $0.28 per share, versus $49.2 million in the year-earlier quarter, and said cash and short-term investments were $209.2 million at June 30, 2026. It also added a Month 24 dual primary endpoint to its Phase 3 ARCHER II trial of vonaprument in geographic atrophy while keeping the Month 15 endpoint on track for Q4 2026, and it entered a credit facility of up to $200 million.
Key points
- Q2 2026 net loss attributable to common stockholders was $55.3 million ($0.28 per share), versus $51.0 million ($0.34 per share) in Q2 2025 as reported in the statement of operations.
- R&D expenses rose to $46.6 million from $44.2 million, and G&A expenses rose to $10.6 million from $7.6 million.
- Cash, cash equivalents and short-term investments were $209.2 million at June 30, 2026; the company expects this plus credit facility funds to support operations into 2028.
- Up to $200 million credit facility with Oxford Finance LLC, with $50 million drawn at closing; Month 15 ARCHER II results expected Q4 2026, Month 24 completion expected Q3 2027.
The filing
Written by AI on Nov 9, 2026, 8:38 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on August 12, 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.